Related Experiment Video

Updated: May 27, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Critical evaluation of the optimal medical therapy in the cardiac resynchronization therapy candidates--single centre

D Vondráková1, F Málek, J Dvorák

  • 1Department of Cardiology, Cardiovascular Centre, Na Homolce Hospital, Prague.

Vnitrni Lekarstvi
|November 22, 2011
PubMed

Insights

Optimal medical therapy for chronic heart failure (CHF) patients receiving cardiac resynchronization therapy with defibrillator (CRTD) significantly improved after treatment optimization. Specialized centers increase the proportion of CHF patients achieving recommended drug doses for better outcomes.

Area of Science:

  • Cardiology
  • Heart Failure Management
  • Medical Device Therapy

Background:

  • Chronic heart failure (CHF) patients referred for cardiac resynchronization therapy with defibrillator (CRTD) often have suboptimal medical therapy.
  • Pre-implantation medication regimens frequently do not meet recommended drug dosages for heart failure management.

Purpose of the Study:

  • To evaluate the effectiveness of optimizing medical therapy in CHF patients undergoing CRTD implantation.
  • To assess changes in medication use and dosage adherence post-CRTD implantation.

Main Methods:

  • Retrospective analysis of 179 CHF patients (NYHA class III-IV) referred for CRTD.
  • Review of medical records to assess pre- and post-implantation optimal medical therapy (OMT).
  • Analysis of the use and dosage of beta-blockers (BB), ACE inhibitors (ACEI), angiotensin receptor blockers (ARB), and spironolactone.

Main Results:

  • Post-CRTD implantation, the use of BB increased significantly (81% to 95%), with a higher proportion reaching 50% of the recommended daily dose.
  • ACEI use also increased post-implantation (68% to 80%), with improved adherence to recommended dosages.
  • Combined ACEI or ARB use rose to 98%, and spironolactone use increased to 77% post-CRTD.

Conclusions:

  • Optimization of medical therapy in a specialized center significantly improves the proportion of CHF patients receiving optimal heart failure treatment.
  • CRTD implantation is associated with enhanced medical therapy management, including increased use and dosage of key heart failure medications.
  • Despite improvements, achieving target drug doses remains a challenge for a subset of CRTD candidates.
Abstract

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

Related Concept Videos

Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...